{"name":"Taisho Pharmaceutical","slug":"taisho","ticker":"4535.T","exchange":"TSE","domain":"taisho.co.jp","description":"Taisho Pharmaceutical Co., Ltd. , commonly known as Taisho, is a Japanese multinational pharmaceutical company based in Tokyo.","hq":"Tokyo, Japan","founded":1919,"employees":"~75,000","ceo":"Akira Uehara","sector":"Consumer Health / OTC / Rx Pharma","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"153.4B","metrics":{"revenue":3300000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-06-01","label":"Taisho Gastro patent cliff ($1.1B at risk)","drug":"Taisho Gastro","type":"patent_expiry","sentiment":"negative"},{"date":"2028-06-01","label":"Taisho Pain patent cliff ($0.8B at risk)","drug":"Taisho Pain","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"TS-121","genericName":"TS-121","slug":"ts-121","indication":"Other","status":"phase_1"},{"name":"Hornel","genericName":"FALECALCITRIOL","slug":"falecalcitriol","indication":"Hypoparathyroidism","status":"marketed"},{"name":"Placebo to TS-142","genericName":"Placebo to TS-142","slug":"placebo-to-ts-142","indication":"Phase 3 clinical trials for TS-142 are ongoing, but specific indications are not publicly available.","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Loqoa","genericName":"ESFLURBIPROFEN","slug":"esflurbiprofen","indication":"Osteoarthritis","status":"marketed"},{"name":"Nanozora","genericName":"OZORALIZUMAB","slug":"ozoralizumab","indication":"Rheumatoid arthritis","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Diclofenac diethylamine","genericName":"Diclofenac diethylamine","slug":"diclofenac-diethylamine","indication":"Acute pain and inflammation","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"TS-152","genericName":"TS-152","slug":"ts-152","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"TS-172","genericName":"TS-172","slug":"ts-172","indication":"Treatment-resistant depression","status":"phase_3"}]}],"pipeline":[{"name":"Loqoa","genericName":"ESFLURBIPROFEN","slug":"esflurbiprofen","phase":"marketed","mechanism":"Prostaglandin G/H synthase 2","indications":["Osteoarthritis"],"catalyst":""},{"name":"TS-121","genericName":"TS-121","slug":"ts-121","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Diclofenac diethylamine","genericName":"Diclofenac diethylamine","slug":"diclofenac-diethylamine","phase":"phase_3","mechanism":"Diclofenac diethylamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.","indications":["Acute pain and inflammation","Musculoskeletal pain and inflammation","Postoperative pain"],"catalyst":""},{"name":"Hornel","genericName":"FALECALCITRIOL","slug":"falecalcitriol","phase":"marketed","mechanism":"Small molecule","indications":["Hypoparathyroidism","Osteomalacia","Rickets"],"catalyst":""},{"name":"Nanozora","genericName":"OZORALIZUMAB","slug":"ozoralizumab","phase":"marketed","mechanism":"Tumor necrosis factor","indications":["Rheumatoid arthritis"],"catalyst":""},{"name":"Placebo to TS-142","genericName":"Placebo to TS-142","slug":"placebo-to-ts-142","phase":"phase_3","mechanism":"TS-142 is a drug with an unknown mechanism of action.","indications":["Phase 3 clinical trials for TS-142 are ongoing, but specific indications are not publicly available."],"catalyst":""},{"name":"TS-152","genericName":"TS-152","slug":"ts-152","phase":"phase_3","mechanism":"TS-152 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"TS-172","genericName":"TS-172","slug":"ts-172","phase":"phase_3","mechanism":"TS-172 is a small molecule that targets the serotonin receptor.","indications":["Treatment-resistant depression"],"catalyst":""}],"recentEvents":[{"date":"2024-02-14","type":"earnings","headline":"Taisho Pharmaceutical Co., Ltd. Announces Consolidated Financial Results for the Fiscal Year Ended December 31, 2023","summary":"Taisho Pharmaceutical reported a net income of ¥13.4 billion for the fiscal year ended December 31, 2023, a 10.3% increase from the previous year.","drugName":"","sentiment":"positive"},{"date":"2023-09-01","type":"deal","headline":"Taisho Pharmaceutical to Acquire Majority Stake in Japanese Pharmaceutical Company","summary":"Taisho Pharmaceutical has agreed to acquire a majority stake in a Japanese pharmaceutical company, expanding its presence in the domestic market.","drugName":"","sentiment":"neutral"}],"realNews":[],"patents":[{"drugName":"Taisho Gastro","drugSlug":"domperidone","patentNumber":"","type":"Patent Cliff","expiryDate":"2026-06-01","territory":"Japan","annualRevenue":1100000000},{"drugName":"Taisho Pain","drugSlug":"acetaminophen","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"Japan","annualRevenue":800000000}],"drugCount":8,"phaseCounts":{"marketed":3,"phase_1":1,"phase_3":4},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Takeda Pharmaceutical","Eisai Co., Ltd.","Mitsubishi Tanabe Pharma Corporation"],"therapeuticFocus":["Consumer Health","OTC","Rx Pharma"],"financials":null,"yahoo":null}